Agneta Nordberg

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. pmc A European multicentre PET study of fibrillar amyloid in Alzheimer's disease
    Agneta Nordberg
    Alzheimer Neurobiology Centre, Geriatric Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 40:104-14. 2013
  2. pmc Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
    Agneta Nordberg
    Karolinska Institutet, Alzheimer Neurobiology Center, Karolinska University, Hospital Huddinge, Novum 5th floor, 141 86 Stockholm, Sweden
    Alzheimers Res Ther 3:34. 2011
  3. doi request reprint The use of PET in Alzheimer disease
    Agneta Nordberg
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Karolinska University Hospital Huddinge, Novum, Stockholm, Sweden
    Nat Rev Neurol 6:78-87. 2010
  4. doi request reprint The future: new methods of imaging exploration in Alzheimer's disease
    Agneta Nordberg
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Front Neurol Neurosci 24:47-53. 2009
  5. ncbi request reprint Amyloid imaging in Alzheimer's disease
    Agneta Nordberg
    Karolinska Institutet, Division of Alzheimer Neurobiology, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Novum 5th floor, S 141 86 Stockholm, Sweden
    Neuropsychologia 46:1636-41. 2008
  6. pmc Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
    Agneta Nordberg
    Karolinska Institute, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Alzheimer Res 6:4-14. 2009
  7. doi request reprint Amyloid imaging in early detection of Alzheimer's disease
    Agneta Nordberg
    Division of Alzheimer Neurobiology, Karolinska Institutet, Karolinska University Hospital Huddinge, Novum 5th floor, SE 141 86 Stockholm, Sweden
    Neurodegener Dis 7:136-8. 2010
  8. doi request reprint Amyloid plaque imaging in vivo: current achievement and future prospects
    Agneta Nordberg
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Novum 5th floor, Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 35:S46-50. 2008
  9. ncbi request reprint Amyloid imaging in Alzheimer's disease
    Agneta Nordberg
    Karolinska Institutet, Division of Molecular Neuropharmacology, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Opin Neurol 20:398-402. 2007
  10. pmc Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Brain 134:301-17. 2011

Detail Information

Publications88

  1. pmc A European multicentre PET study of fibrillar amyloid in Alzheimer's disease
    Agneta Nordberg
    Alzheimer Neurobiology Centre, Geriatric Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 40:104-14. 2013
    ..To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies...
  2. pmc Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
    Agneta Nordberg
    Karolinska Institutet, Alzheimer Neurobiology Center, Karolinska University, Hospital Huddinge, Novum 5th floor, 141 86 Stockholm, Sweden
    Alzheimers Res Ther 3:34. 2011
    ..Functional biomarkers such as regional cerebral glucose metabolism together with measurement of the brain volumes provide valuable information about disease progression and outcome of drug treatment...
  3. doi request reprint The use of PET in Alzheimer disease
    Agneta Nordberg
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Karolinska University Hospital Huddinge, Novum, Stockholm, Sweden
    Nat Rev Neurol 6:78-87. 2010
    ..For the near future, multitracer PET studies are unlikely to be used routinely in the clinic for AD, being both burdensome and expensive; however, such studies are very informative in a research context...
  4. doi request reprint The future: new methods of imaging exploration in Alzheimer's disease
    Agneta Nordberg
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Front Neurol Neurosci 24:47-53. 2009
    ....
  5. ncbi request reprint Amyloid imaging in Alzheimer's disease
    Agneta Nordberg
    Karolinska Institutet, Division of Alzheimer Neurobiology, and Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Novum 5th floor, S 141 86 Stockholm, Sweden
    Neuropsychologia 46:1636-41. 2008
    ..This opens up new possibilities for early diagnosis as well as new tools for monitoring anti-amyloid therapy in AD...
  6. pmc Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
    Agneta Nordberg
    Karolinska Institute, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Alzheimer Res 6:4-14. 2009
    ....
  7. doi request reprint Amyloid imaging in early detection of Alzheimer's disease
    Agneta Nordberg
    Division of Alzheimer Neurobiology, Karolinska Institutet, Karolinska University Hospital Huddinge, Novum 5th floor, SE 141 86 Stockholm, Sweden
    Neurodegener Dis 7:136-8. 2010
    ..PET Abeta imaging will also be used for discrimination of AD from other dementia disorders, as well for the evaluation of anti-Abeta drugs...
  8. doi request reprint Amyloid plaque imaging in vivo: current achievement and future prospects
    Agneta Nordberg
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Novum 5th floor, Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 35:S46-50. 2008
    ..Despite a probable whole cascade of events in the brain leading to impairment of cognition, amyloid is still the target for diagnosis and treatment...
  9. ncbi request reprint Amyloid imaging in Alzheimer's disease
    Agneta Nordberg
    Karolinska Institutet, Division of Molecular Neuropharmacology, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Opin Neurol 20:398-402. 2007
    ..This paper reviews the progress in developing amyloid imaging ligands to be used to measure amyloid in vivo in the brain of patients with Alzheimer's disease...
  10. pmc Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Brain 134:301-17. 2011
    ....
  11. ncbi request reprint Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein
    Jin Xiu
    Neurotec Department, Division of Molecular Neuropharmacology, Karolinska Institutet, Stockholm, Sweden
    J Neurosci Res 82:531-41. 2005
    ..We also show that the up-regulation of alpha7 nAChRs stimulated by lovastatin is involved in a mechanism that enhances production of alphaAPPs during APP processing...
  12. doi request reprint Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
    Michael Scholl
    Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden
    Neurology 79:229-36. 2012
    ..To investigate the particular pathology of the Arctic APP (APParc) early-onset familial Alzheimer disease (eoFAD) mutation for the first time in vivo with PET in comparison with other eoFAD mutations and sporadic Alzheimer disease (sAD)...
  13. ncbi request reprint Selective nicotinic receptor consequences in APP(SWE) transgenic mice
    Ivan Bednar
    Divisions of Molecular Neuropharmacology, Occupational Therapy and Elderly Care Research NEUROTEC, S 141 86 Stockholm, Sweden
    Mol Cell Neurosci 20:354-65. 2002
    ..The upregulation of the nAChRs probably reflects compensatory mechanisms in response to Abeta burden in the brains of Tg+ mice...
  14. ncbi request reprint Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice
    Ewa Hellström-Lindahl
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge B84, S 141 86 Stockholm, Sweden
    Eur J Neurosci 19:2703-10. 2004
    ..Further studies are required to identify potential mechanisms of the nicotine's amyloid-reducing effect...
  15. ncbi request reprint Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET
    Ahmadul Kadir
    Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum floor 5, 141 86, Stockholm, Sweden
    Psychopharmacology (Berl) 191:1005-14. 2007
    ..Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD...
  16. doi request reprint Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 34:2465-81. 2013
    ..Further studies are needed to explore the therapeutic potential of manipulating BuChE activity or astroglial functional status...
  17. ncbi request reprint Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice
    Christina Unger
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Pharmacol Exp Ther 317:30-6. 2006
    ..These different effects might have therapeutic relevance, and this knowledge might be applicable to the development of new effective therapeutic strategies for AD...
  18. pmc Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels
    Anna M Lilja
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 8:e58752. 2013
    ..In contrast, lowering Aβ levels in Tg2576 mice when Aβ plaque pathology is prominent mainly alters the levels of proinflammatory cytokines and chemokines...
  19. pmc ³H-deprenyl and ³H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain
    Amelia Marutle
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum floor 5, Stockholm S 14186, Sweden
    J Neuroinflammation 10:90. 2013
    ..This information could aid the development of specific biomarkers to accurately chart disease progression...
  20. doi request reprint Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity
    Fuxiang Bao
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 33:825.e1-13. 2012
    ..These novel findings suggest that distinct Aβ oligomers induce impairment of cholinergic neurotransmission in AD pathogenesis...
  21. doi request reprint Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:2320.e15-32. 2011
    ....
  22. ncbi request reprint PET imaging of amyloid deposition in patients with mild cognitive impairment
    Anton Forsberg
    Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    Neurobiol Aging 29:1456-65. 2008
    ..01). The PIB retention in MCI converters was comparable to AD patients (p>0.01). Correlations were observed in the MCI patients between PIB retention and CSF Abeta(1-42), total Tau and episodic memory, respectively...
  23. doi request reprint Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease
    Maria Eriksdotter-Jonhagen
    Departments of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden maria eriksdotter jonhagen ki se
    Dement Geriatr Cogn Disord 33:18-28. 2012
    ..Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability...
  24. doi request reprint Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Neurobiol Aging 33:198.e1-14. 2012
    ..The rCMRglc starts to decline in MCI patients and became more pronounced in clinical stage which related to continuous decline in cognition...
  25. ncbi request reprint Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw)
    Agneta Nordberg
    Karolinska Institutet, Neurotec, Division of Molecular Neuropharmacology, Huddinge University Hospital, Stockholm, Sweden
    J Neurochem 81:655-8. 2002
    ..These results indicate that nicotine may effectively reduce amyloid beta peptide aggregation in brain and that nicotinic drug treatment may be a novel protective therapy in Alzheimer's disease...
  26. doi request reprint Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice
    Monika M Hedberg
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Neurodegener Dis 7:379-88. 2010
    ..In this study, the aim was to investigate whether HX could affect the AD-related neuropathology in vivo in two mouse models...
  27. ncbi request reprint Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
    Ruiqing Ni
    Alzheimer Neurobiology Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Brain 136:2217-27. 2013
    ..BF-227 shows mainly binding to site 3 and FDDNP shows only some binding to site 2. Different amyloid tracers may provide new insight into the pathophysiological mechanisms in the progression of Alzheimer's disease...
  28. ncbi request reprint PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Novum floor 5, Stockholm, 141 86, Sweden
    Psychopharmacology (Berl) 188:509-20. 2006
    ..The alpha4 and alpha7 nAChR subunits were suggested to play an important role in cognitive function. Positron emission tomography (PET) has so far been used to visualize neuronal nAChRs in vivo by 11C-nicotine binding...
  29. doi request reprint Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers
    Michael Scholl
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    J Alzheimers Dis 24:495-506. 2011
    ..We here show that FDG PET can depict in vivo the aggressive disease progression in eoFAD mutation carriers in relationship to neuropathology...
  30. ncbi request reprint Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid
    Malahat Mousavi
    Karolinska Institute, Department of Neurotec, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum 5th floor, S 14186 Stockholm, Sweden
    Int J Dev Neurosci 24:269-73. 2006
    ..The findings may have implications for a better understanding the underlying mechanism for AD-related pathogenesis...
  31. doi request reprint Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients
    Il Han Choo
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Alzheimers Dis 33:929-39. 2013
    ..In conclusion, our findings highlight that the combination of regional glucose metabolic assessment by PET and CSF biomarkers evaluation can significantly improve AD predictive diagnostic accuracy of each respective method...
  32. ncbi request reprint Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells
    Julia Roensch
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Stockholm, Sweden
    Neurochem Int 50:800-6. 2007
    ....
  33. ncbi request reprint High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques
    Wen Feng Yu
    Division of Molecular Neuropharmacology, Neurotec Department, Karolinska Institutet, Karolinska University Hospital Huddinge, B84, S 141 86 Stockholm, Sweden
    Exp Neurol 192:215-25. 2005
    ..The elevated expression of alpha7 nAChR on astrocytes might participate in Abeta cascade and formation of neuritic plaques, thereby playing an important role in the pathogenesis of AD...
  34. ncbi request reprint The use of PIB-PET as a dual pathological and functional biomarker in AD
    Anton Forsberg
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    Biochim Biophys Acta 1822:380-5. 2012
    ..This might be important for diagnosis of AD, enrichment of patients in clinical trials and evaluation of treatment effects. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease...
  35. doi request reprint Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain
    Ruiqing Ni
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Alzheimers Dis 33:841-51. 2013
    ....
  36. ncbi request reprint Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells
    Zhi zhong Guan
    Division of Molecular Neuropharmacology, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research, Karolinska Institutet, Huddinge University Hospital B84, SE 141 86 Stockholm, Sweden
    Neurochem Int 43:243-9. 2003
    ..Generally, high dose of nicotine may induce neurotoxicity and stimulate oxidative stress, while reasonably low concentration may act as an antioxidant and play an important role for neuroprotective effect...
  37. pmc Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease
    Anna M Lilja
    Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    PLoS ONE 8:e54887. 2013
    ....
  38. doi request reprint Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG
    Stephen F Carter
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    J Nucl Med 53:37-46. 2012
    ..Along with (11)C-DED PET, (11)C-Pittsburgh compound B ((11)C-PIB; fibrillar Aβ deposition), (18)F-FDG (glucose metabolism), T1 MRI, cerebrospinal fluid, and neuropsychologic data were acquired from the patients...
  39. ncbi request reprint Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase
    Marie M Svedberg
    Division of Molecular Neuropharmacology, Department of Neurotec, Karolinska Institutet, Huddinge University Hospital B84, S 141 86 Stockholm, Sweden
    Neuropharmacology 47:558-71. 2004
    ..This study shows regional and receptor subtype specific changes in the nicotinic receptor subtypes compared to the muscarinic receptors following galantamine treatment in FVB/N and hAChE-Tg mice...
  40. pmc Β-amyloid 1-42 oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons
    Linn Wicklund
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 5:e15600. 2010
    ..We propose that it may be possible for future AD therapies to promote the maturation of functional stem cell-derived neurons by altering the brain microenvironment with trophic support and by targeting different aggregation forms of Aβ...
  41. ncbi request reprint Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinestrase
    Malahat Mousavi
    Department of Neurotec, Division of Molecular Neuropharmacology, Karolinska Institute, Karolinska University Hospital, Huddinge B84, S 141 86 Stockholm, Sweden
    Int J Dev Neurosci 22:545-9. 2004
    ..Deposition of beta-amyloid (Abeta) may impair neurotransmitter activity in brain as well as in the adrenal gland...
  42. ncbi request reprint Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells
    Mats Nilbratt
    Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Neurosci Res 85:504-14. 2007
    ..The present results show that RA and NGF have different effects on the expression of ChAT and the morphology and the expression pattern of different nAChR subunits in cholinergic SN56 cells...
  43. doi request reprint Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Sweden
    Ann Neurol 63:621-31. 2008
    ....
  44. ncbi request reprint Higher expression of alpha7 nicotinic acetylcholine receptors in human fetal compared to adult brain
    Lena Falk
    Neurotec Department, Division of Molecular Neuropharmacology, Huddinge University Hospital, S 141 86, Stockholm, Sweden
    Brain Res Dev Brain Res 142:151-60. 2003
    ..The high expression of alpha7 nicotinic acetylcholine receptors in fetal compared to adult brain supports the view that these receptors play an important role during brain development...
  45. ncbi request reprint Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase
    Marie M Svedberg
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, Huddinge University Hospital, S 141 86 Stockholm, Sweden
    Neurosci Lett 340:148-52. 2003
    ....
  46. ncbi request reprint Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1-42)
    Jin Xiu
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, B84, S 14186 Stockholm, Sweden
    Neurochem Int 47:281-90. 2005
    ..We propose that the enhanced expression of alpha7, alpha4 and beta2 nAChRs by astrocytes stimulated directly by nanomolar concentrations of Abeta(1-42) might be related to ongoing defensive or compensative mechanisms...
  47. ncbi request reprint Early changes in Abeta levels in the brain of APPswe transgenic mice--implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels
    Christina Unger
    Karolinska Institutet, Department of Neurotec, Division of Molecular Neuropharmacology, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    Mol Cell Neurosci 30:218-27. 2005
    ..The results may provide important information about the onset and consequences of Abeta pathology in this transgenic mouse model...
  48. ncbi request reprint Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons
    Mats Nilbratt
    Karolinska Institutet, Karolinska University Hospital Huddinge, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    J Cell Mol Med 14:1476-84. 2010
    ....
  49. ncbi request reprint Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice
    Amelia Marutle
    Division of Molecular Neuropharmacology, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Karolinska Institutet, Huddinge University Hospital, B84, 141 86, Stockholm, Sweden
    Neurosci Lett 328:269-72. 2002
    ..The findings indicate that elevated Abeta levels in the brains of APPswe/PS1 mice do not alter the number of alpha4beta2 and alpha7 receptors, the two major brain nAChR subtypes...
  50. ncbi request reprint Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease
    Agneta Nordberg
    Neurotec Department, Division of Molecular Neuropharmacology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Alzheimer Dis Assoc Disord 20:S12-8. 2006
    ..If such experimental in vitro observations can be extrapolated into clinical neuroprotective properties, AChE inhibitors could positively modulate the disease course of AD...
  51. ncbi request reprint Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes
    Jin Xiu
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, 141 86 Stockholm, Sweden
    Neurochem Int 49:459-65. 2006
    ....
  52. ncbi request reprint Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease
    Zhi zhong Guan
    Karolinska Institutet, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research NEUROTEC, Division of Molecular Neuropharmacology, Huddinge University Hospital, B84, S 141 86 Stockholm, Sweden
    Brain Res 956:358-66. 2002
    ..These findings reveal selective losses of the alpha3- and beta2-containing nAChRs and an increase in the alpha7 nAChRs that might be related to the pathogenesis of PD...
  53. ncbi request reprint Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    J Alzheimers Dis 28:443-58. 2012
    ..APOE4-dependent outcome of BCHE-K genotype as AD risk factor arises through a differential phenotypic modulation of BuChE. Future pharmacogenetic studies should include assessment of the subjects' true phenotypic display of BuChE...
  54. doi request reprint Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice
    Tamanna Mustafiz
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
    Neurodegener Dis 8:352-63. 2011
    ..Our objective was to investigate the consequences of Aβ, especially on tau phosphorylation at specific epitopes important for Alzheimer's disease...
  55. doi request reprint Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease
    Anna M Lilja
    Karolinska Institutet, Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Alzheimers Dis 23:335-47. 2011
    ..Our findings demonstrate that fibrillar Aβ exerts neurotoxic effects mediated partly through a blockade of α7 nAChRs, whilst oligomeric Aβ may act as a ligand activating α7 nAChRs, thereby stimulating downstream signaling pathways...
  56. doi request reprint Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
    Michael Scholl
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:1388-99. 2011
    ..Global cortical CMRglc and cognition were distinctly decreased. PIB binding was comparable with sporadic AD patterns but showing slightly higher striatal levels...
  57. doi request reprint The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
    Taher Darreh-Shori
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Sweden
    Neurobiol Aging 32:1236-48. 2011
    ..In conclusion, ApoE ε4 might impart its pathological role through high protein expression and interaction with BuChE, which in turn might modulate central cholinergic activity and Aβ load in the brain...
  58. ncbi request reprint Toward an early diagnosis and treatment of Alzheimer's disease
    Agneta Nordberg
    Karolinska Institutet, Neurotec Department, Division of Molecular Neuropharmacology, Huddinge University Hospital, Stockholm, Sweden
    Int Psychogeriatr 15:223-37. 2003
    ..There is a great optimism for early diagnosis and effective treatment of AD in the future...
  59. doi request reprint Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients
    Connor Keller
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Alzheimers Dis 24:109-23. 2011
    ..This stabilization in rCMRglc was also correlated with a stabilization of cognition. Our results ultimately suggest that treatment with galantamine has a long-term positive effect on brain perfusion and rCMRglc and stabilizes cognition...
  60. pmc Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation
    Marjan Shafaati
    Department of Laboratory Medicine Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
    J Lipid Res 52:1004-10. 2011
    ..We discuss the possibility of a vicious circle in the brains of the patients with familial AD whereby neurodegenerative changes cause an accumulation of 27OHC that further accelerates neurodegeneration...
  61. ncbi request reprint Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats
    Ivan Bednar
    Department of Neurotec, Division of Molecular Neuropharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, SE 14186 Stockholm, Sweden
    Neurochem Int 45:1049-55. 2004
    ..Different mechanisms in modulation of DA release appears to be involved in the rat brain by (+/-)epibatidine compare to (-)nicotine...
  62. ncbi request reprint Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation
    Zhi zhong Guan
    Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research, Division of Molecular Neuropharmacology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Neurosci Res 71:397-406. 2003
    ..These findings suggest that lipid peroxidation stimulated by A betas might be a mechanism for the loss of nAChRs associated with the pathogenesis of AD...
  63. ncbi request reprint Correlation of oxidative stress and the loss of the nicotinic receptor alpha 4 subunit in the temporal cortex of patients with Alzheimer's disease
    Wen Feng Yu
    Karolinska Institutet, Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research, Division of Molecular Neuropharmacology, Huddinge University Hospital, B84, S 141 86 Stockholm, Sweden
    Neurosci Lett 338:13-6. 2003
    ..We suggest that lipid peroxidation might be a sensitive target in AD brain and related the mechanism of the loss of the nAChR alpha4 subunit in the disease...
  64. ncbi request reprint Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?
    Agneta Nordberg
    Neurotec Department, Karolinska Institutet, Karolinska University Hospital Huddinge B84, 141 86 Stockholm, Sweden
    Eur J Nucl Med Mol Imaging 31:1540-3. 2004
  65. ncbi request reprint Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase
    Marie M Svedberg
    Karolinska Institutet, Neurotec, Division of Molecular Neuropharmacology, Huddinge University Hospital, Stockholm, Sweden
    J Mol Neurosci 18:211-22. 2002
    ....
  66. ncbi request reprint Smoking during pregnancy: a way to transfer the addiction to the next generation?
    Ewa Hellström-Lindahl
    Karolinska Institutet, Neurotec, Division of Molecular Neuropharmacology, Huddinge University Hospital, Stockholm, Sweden
    Respiration 69:289-93. 2002
    ..A direct specific action on the developing human brain is plausible during the major part of the prenatal life, since the nicotinic receptors are already present in the brain during the first trimester...
  67. pmc Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine
    Amelia Marutle
    Biomolecular Sciences Center, Burnett College of Biomedical Sciences, University of Central Florida, Orlando, FL 32816, USA
    Proc Natl Acad Sci U S A 104:12506-11. 2007
    ....
  68. ncbi request reprint Transgenic mice as a model for Alzheimer's disease
    Christina Unger Lithner
    Karolinska Institutet, NVS, Division of Alzheimer Neurobiology, Novum Floor 4, Karolinska University Hospital, Huddinge, S 141 86 Stockholm, Sweden
    Curr Alzheimer Res 8:818-31. 2011
    ....
  69. ncbi request reprint Target-specific PET probes for neurodegenerative disorders related to dementia
    Ahmadul Kadir
    Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Nucl Med 51:1418-30. 2010
    ..The development of molecular imaging is important for early diagnosis of dementia, selection of patients for therapies, and evaluation of therapies...
  70. ncbi request reprint PET imaging of amyloid in Alzheimer's disease
    Agneta Nordberg
    Karolinska Institute, Neurotec Department, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Lancet Neurol 3:519-27. 2004
    ..Additional compounds will probably be developed that are suitable not only for PET but also for single photon emission CT (SPECT)...
  71. ncbi request reprint Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures
    Roxana Nat
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden
    Glia 55:385-99. 2007
    ..Our system successfully generates human RG cells and could be an effective source for neuronal replacement, since RG cells predominantly generate neurons and provide them with support and guidance...
  72. ncbi request reprint A critical discussion of the role of neuroimaging in mild cognitive impairment
    Henrike Wolf
    Karolinska Institutet, Neurotec, Division of Geriatric Medicine, Huddinge University Hospital, Sweden
    Acta Neurol Scand Suppl 179:52-76. 2003
    ..Particular attention is drawn to the possible value of neuroimaging modalities in the prediction and early diagnosis of Alzheimer's disease (AD)...
  73. ncbi request reprint Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique
    Agneta Nordberg
    Karolinska Institute, Neurotec Department, Division of Molecular Neuropharmacology, Huddinge University Hospital, S 141 86 Stockholm, Sweden
    Prog Brain Res 145:301-10. 2004
  74. ncbi request reprint The alpha7 nicotinic receptors in human fetal brain and spinal cord
    Lena Falk
    Department of Clinical Neuroscience, Occupational Therapy and Elderly Care Research, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    J Neurochem 80:457-65. 2002
    ..The increasing levels of the alpha7 nicotinic acetylcholine receptor during the first trimester support the important role of nAChRs for the development of the central nervous system...
  75. ncbi request reprint Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice
    Nagat Abbas
    Division of Geriatric Medicine B84, Karolinska Institute, Huddinge University Hospital, S 141 86 Stockholm, Sweden
    J Neuroimmunol 126:50-7. 2002
    ..These observations call for further studies on the potential role of anti-inflammatory therapeutic strategies for AD...
  76. ncbi request reprint High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters
    A Forsberg
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Alzheimer Res 7:56-66. 2010
    ..In this study we investigated how (11)C-PIB retention is related to cerebral glucose metabolism, episodic memory and CSF biomarkers...
  77. ncbi request reprint Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
    Henry Engler
    Uppsala Imanet AB, Imanet, GE Healthcare Uppsala University, Uppsala
    Brain 129:2856-66. 2006
    ..FDG imaging may be able to detect a stabilization of cerebral metabolism caused by therapy administered to patients with a clinical diagnosis of Alzheimer's disease...
  78. ncbi request reprint Chronic fluoride toxicity decreases the number of nicotinic acetylcholine receptors in rat brain
    Yi Guo Long
    Department of Pathology, Guiyang Medical College, Guizhou, PR China
    Neurotoxicol Teratol 24:751-7. 2002
    ..Since nAChRs play major roles in cognitive processes such as learning and memory, the decrease in the number of nAChRs caused by fluoride toxicity may be an important factor in the mechanism of brain dysfunction in the disorder...
  79. ncbi request reprint Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
    William E Klunk
    Department of Psychiatry, PET Facility, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
    Ann Neurol 55:306-19. 2004
    ..This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects...
  80. ncbi request reprint Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography
    William E Klunk
    Laboratory of Molecular Neuropharmacology, Department of Psychiatry, University of Pittsburgh School of Medicine, 705 Parran Hall, Pittsburgh, PA 15213, USA
    Neuroimaging Clin N Am 13:781-9, ix. 2003
    ..The capability to use positron emission tomography and selective markers for amyloid protein deposition promises to substantially alter the way we diagnosis and manage patients who have AD...
  81. ncbi request reprint The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenes
    Xiao lan Qi
    Department of Pathology and Molecular Biology, Guiyang Medical University, Guiyang 550004, Guizhou, PR China
    Neurochem Int 51:377-83. 2007
    ....
  82. ncbi request reprint Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity--a mechanism relating to a damage at the level in post-transcription of the receptor genes
    Ke Ren Shan
    Department of Molecular Biology, Guiyang Medical College, 550004, Guizhou, PR China
    Toxicology 200:169-77. 2004
    ..The results suggest that the deficit of nAChRs induced by fluoride toxicity occurs at the level of post-transcription of the receptor gene, in which a mechanism might be involved in the damage by oxidative stress...
  83. doi request reprint Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
    Roger Lane
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
    Pharmacogenet Genomics 18:289-98. 2008
    ..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)...
  84. ncbi request reprint [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]
    Agneta Nordberg
    Geriatriska kliniken, Karolinska Universitetssjukhuset, Huddinge
    Lakartidningen 103:369-71. 2006
  85. ncbi request reprint Feedback regulation of SREBP and aromatase in A beta(25-35)-supplemented human neuroblastoma cells
    Pelin Kelicen
    Faculty of Pharmacy, Department of Pharmacology, Hacettepe University, 06100 Sihhiye, Ankara, Turkey
    Cell Mol Neurobiol 26:225-35. 2006
    ..These findings may have important implications for understanding the mechanisms of the aromatase enzyme gene in disease states such as Alzheimer's...
  86. ncbi request reprint Selective decreases of nicotinic acetylcholine receptors in PC12 cells exposed to fluoride
    Jia Chen
    Department of Pathology, Guiyang Medical College, Guiyang 550004, Guizhou, PR China
    Toxicology 183:235-42. 2003
    ..These findings suggest that selective decreases in the number of nAChRs may play an important role in the mechanism(s) by which fluoride causes dysfunction of the central nervous system...
  87. ncbi request reprint [Don't underestimate the value of transgenic animal models of Alzheimer disease]
    Lars N G Nilsson
    Uppsala universitet
    Lakartidningen 104:798-9; discussion 799-800. 2007
  88. ncbi request reprint A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?
    Paul T Francis
    Wolfson Centre for Age Related Diseases, Guy s Campus, St Thomas Street, Kings College London, London SE1 1UL, UK
    Trends Pharmacol Sci 26:104-11. 2005
    ..The mechanisms by which these actions are mediated might or might not be directly related to their primary mode of action...